As such, these IC genes merit further exploration for their possible differential expression in cancer and their potential as immunotherapy targets in renal cell carcinomas, which are currently treated with PD-1 and CTLA-4-blocking therapeutics [50]. This evidence concerns the gene CTLA4 and cancer.